Xenograft rejection: IgG1, complement and NK cells team up to activate and destroy the endothelium
Publisher DOI
PubMed ID
15629401
Abstract
Acute vascular rejection represents a formidable barrier to clinical xenotransplantation and it is known that this type of rejection can also be initiated by xenoreactive antibodies that have limited complement-activating ability. Using a sophisticated mouse model, a recent study has provided in vivo evidence for the existence of an IgG(1)-mediated vascular rejection, which uniquely depends on both the activation of complement and interactions with FcgammaRIII on natural killer (NK) cells.
Date Issued
2005
Publication Type
Article
Language(s)
en
Author(s)
Seebach, Jörg D |
Journal
Trends in immunology
Publisher
Elsevier Current Trends
ISSN
1471-4906
Access(Rights)
metadata.only